Skip to main content
Type at least 3 characters

605 articles

Original Research

Published on 29 Mar 2023

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

in Respiratory Pharmacology

  • Daniel Morales-Cano
  • Jose Luis Izquierdo-García
  • Bianca Barreira
  • Sergio Esquivel-Ruiz
  • Maria Callejo
  • Rachele Pandolfi
  • Palmira Villa-Valverde
  • Ignacio Rodríguez
  • Angel Cogolludo
  • Jesus Ruiz-Cabello
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1021535
  • 4,081 views
  • 5 citations